TileBio closes £2.261M seed round

TileBio has closed its seed round at £2.261 million. The round was led by Twin Path Ventures, with follow-on investment from Maven Capital Partners, Scottish Enterprise, the University of Glasgow and the Smart Things Accelerator Centre (STAC).

This follows our announcement of £1.6 million in seed funding in February 2026.

What the funding is for

The funding will be used to validate our technology in de-risking the drug development pipeline. Our tissue-language foundation model learns directly from unlabelled whole-slide images, and we are applying it first in two areas:

• Preclinical toxicology: flagging and quantifying treatment-related morphology consistently across studies. This is the focus of TileBio Precedent.
• Exploratory biomarker discovery: identifying tissue phenotypes associated with outcome and treatment response in partner cohorts. This is the focus of TileBio Motif.

What comes next

Validation in these two areas is the basis for our Series A raise, and for our longer-term roadmap toward clinical diagnostics.

Our investors

• Twin Path Ventures (lead investor)
• Maven Capital Partners
• Scottish Enterprise
• University of Glasgow
• Smart Things Accelerator Centre (STAC)

We are grateful to all of our investors for their support, and to our partners at NHS Greater Glasgow & Clyde and the NHS West of Scotland Innovation Hub.

To discuss a pilot or a collaboration, get in touch.